PCI Biotech - Financial calendar for 2010:

(Thomson Reuters ONE) - 19 February 2010 - Presentation of the fourth quarter 2009 report27 April 2010 - Presentation of the first quarter 2010 report27 April 2010 - Annual General Meeting24 August 2010 - Presentation of the second quarter 2010 report26 October 2010 - Presentation of the third quarter 2010 reportFor further information, please contact:Bernt-Olav RøttingsnesCFO/IROEmail: bor(at)pcibiotech.noMobile +47 913 47 021This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 02.11.2009 - 09:31 Uhr
Sprache: Deutsch
News-ID 7745
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 248 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"PCI Biotech - Financial calendar for 2010:"
steht unter der journalistisch-redaktionellen Verantwortung von

PCI Biotech Holding (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Can ...

PCI Biotech has initiated pre-clinical trials for the use of Photochemical Internalisation (PCI) in the treatment of Bladder cancer. The pre-clinical trials will be concluded during the first half of 2010, and a phase I/II study (first in man) is exp ...

3rd Quarter 2009 Report ...

Oslo, Norway, 27 October 2009. Please find attached the third quarter report 2009 for PCI Biotech Holding ASA. Kind regards, Per Walday CEO Email: pw@pcibiotech.no Mobil: +47 917 93 429 http://hugin.info/139147/R/1350200/325656.pdf This annou ...

Successful completion of the first dose group in the Phase I/II study of Amphine ...

Oslo, 19 October 2009 - PCI Biotech has completed the treatment of the first dose group in the phase I/II study of Amphinex® in cancer patients. No serious adverse events have been recorded and tumour response was seen even at this low dose. The stu ...

Alle Meldungen von PCI Biotech Holding